# Celestimo (NCT04712097)

> A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04712097
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Relapsed or Refractory Follicular Lymphoma
- Interventions: Mosunetuzumab; Lenalidomide; Rituximab; Tociluzumab
- Enrollment: 478
- Primary outcome: Progression Free Survival (PFS) according to 2014 Lugano Response Criteria

## Commentary we found

- YouTube: 17
- Podcasts: 6
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=celestimo-nct04712097

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04712097", "email": "<work email>"}; the inbox owner confirms by the emailed link.